How to buy Lexicon Pharmaceuticals stock

Lexicon Pharmaceuticals, Inc is a biotechnology business based in the US. Lexicon Pharmaceuticals shares (LXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Lexicon Pharmaceuticals employs 184 staff and has a trailing 12-month revenue of around USD$32.5 million.

How to buy shares in Lexicon Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Lexicon Pharmaceuticals. Find the stock by name or ticker symbol: LXRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Lexicon Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Lexicon Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Lexicon Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Lexicon Pharmaceuticals share price

Use our graph to track the performance of LXRX stocks over time.

Lexicon Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-02-24.

52-week range	USD$1.03 - USD$9.43
50-day moving average	USD$7.1939
200-day moving average	USD$3.1489
Wall St. target price	USD$8
PE ratio	3.7419
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.369

Buy Lexicon Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lexicon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lexicon Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lexicon Pharmaceuticals financials

Revenue TTM	USD$32.5 million
Gross profit TTM	USD$226.9 million
Return on assets TTM	-42.76%
Return on equity TTM	-82.6%
Profit margin	0%
Book value	$0.753
Market capitalisation	USD$1.1 billion

TTM: trailing 12 months

Shorting Lexicon Pharmaceuticals shares

There are currently 5.4 million Lexicon Pharmaceuticals shares held short by investors – that's known as Lexicon Pharmaceuticals's "short interest". This figure is 52.9% down from 11.4 million last month.

There are a few different ways that this level of interest in shorting Lexicon Pharmaceuticals shares can be evaluated.

Lexicon Pharmaceuticals's "short interest ratio" (SIR)

Lexicon Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Lexicon Pharmaceuticals shares currently shorted divided by the average quantity of Lexicon Pharmaceuticals shares traded daily (recently around 11.2 million). Lexicon Pharmaceuticals's SIR currently stands at 0.48. In other words for every 100,000 Lexicon Pharmaceuticals shares traded daily on the market, roughly 480 shares are currently held short.

However Lexicon Pharmaceuticals's short interest can also be evaluated against the total number of Lexicon Pharmaceuticals shares, or, against the total number of tradable Lexicon Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lexicon Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Lexicon Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0847% of the tradable shares (for every 100,000 tradable Lexicon Pharmaceuticals shares, roughly 85 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lexicon Pharmaceuticals.

Find out more about how you can short Lexicon Pharmaceuticals stock.

Have Lexicon Pharmaceuticals's shares ever split?

Lexicon Pharmaceuticals's shares were split on a 1:7 basis on 21 May 2015. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexicon Pharmaceuticals shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Lexicon Pharmaceuticals shares which in turn could have impacted Lexicon Pharmaceuticals's share price.

Lexicon Pharmaceuticals share price volatility

Over the last 12 months, Lexicon Pharmaceuticals's shares have ranged in value from as little as $1.03 up to $9.43. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexicon Pharmaceuticals's is 1.7252. This would suggest that Lexicon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Lexicon Pharmaceuticals overview

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Frequently asked questions

• What percentage of Lexicon Pharmaceuticals is owned by insiders or institutions?

  Currently 0.898% of Lexicon Pharmaceuticals shares are held by insiders and 91.962% by institutions.

• How many people work for Lexicon Pharmaceuticals?

  Latest data suggests 184 work at Lexicon Pharmaceuticals.

• When does the fiscal year end for Lexicon Pharmaceuticals?

  Lexicon Pharmaceuticals's fiscal year ends in December.

• Where is Lexicon Pharmaceuticals based?

  Lexicon Pharmaceuticals's address is: 8800 Technology Forest Place, The Woodlands, TX, United States, 77381-1160

• What is Lexicon Pharmaceuticals's ISIN number?

  Lexicon Pharmaceuticals's international securities identification number is: US5288723027

• What is Lexicon Pharmaceuticals's CUSIP number?

  Lexicon Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 528872104